These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

135 related articles for article (PubMed ID: 30178392)

  • 1. ASO Author Reflections: BRCA Mutation Status for Personalizing Management of Recurrent Ovarian Cancer-A Multicenter Study.
    Fagotti A
    Ann Surg Oncol; 2018 Nov; 25(12):3709-3710. PubMed ID: 30178392
    [No Abstract]   [Full Text] [Related]  

  • 2. BRCA Mutation Status to Personalize Management of Recurrent Ovarian Cancer: A Multicenter Study.
    Marchetti C; De Leo R; Musella A; D'Indinosante M; Capoluongo E; Minucci A; Benedetti Panici P; Scambia G; Fagotti A
    Ann Surg Oncol; 2018 Nov; 25(12):3701-3708. PubMed ID: 30128899
    [TBL] [Abstract][Full Text] [Related]  

  • 3. BRCA mutational status, initial disease presentation, and clinical outcome in high-grade serous advanced ovarian cancer: a multicenter study.
    Petrillo M; Marchetti C; De Leo R; Musella A; Capoluongo E; Paris I; Benedetti Panici P; Scambia G; Fagotti A
    Am J Obstet Gynecol; 2017 Sep; 217(3):334.e1-334.e9. PubMed ID: 28549976
    [TBL] [Abstract][Full Text] [Related]  

  • 4. BRCA1 and BRCA2 mutations in males with familial breast and ovarian cancer syndrome. Results of a Spanish multicenter study.
    de Juan I; Palanca S; Domenech A; Feliubadaló L; Segura Á; Osorio A; Chirivella I; de la Hoya M; Sánchez AB; Infante M; Tena I; Díez O; Garcia-Casado Z; Vega A; Teulé À; Barroso A; Pérez P; Durán M; Carrasco E; Juan-Fita MJ; Murria R; Llop M; Barragan E; Izquierdo Á; Benítez J; Caldés T; Salas D; Bolufer P
    Fam Cancer; 2015 Dec; 14(4):505-13. PubMed ID: 26026974
    [TBL] [Abstract][Full Text] [Related]  

  • 5. A population-based analysis of germline BRCA1 and BRCA2 testing among ovarian cancer patients in an era of histotype-specific approaches to ovarian cancer prevention.
    Hanley GE; McAlpine JN; Miller D; Huntsman D; Schrader KA; Blake Gilks C; Mitchell G
    BMC Cancer; 2018 Mar; 18(1):254. PubMed ID: 29506471
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Adjuvant Oophorectomy in the Treatment of Early-Stage BRCA Mutation-Positive Breast Cancer.
    Disis ML
    JAMA Oncol; 2015 Jun; 1(3):313. PubMed ID: 26181176
    [No Abstract]   [Full Text] [Related]  

  • 7. Rucaparib for recurrent ovarian cancer with BRCA1 and BRCA2 mutations.
    Ganguly S; Gogia A
    Lancet Oncol; 2022 Jul; 23(7):e314. PubMed ID: 35772456
    [No Abstract]   [Full Text] [Related]  

  • 8. Rucaparib for recurrent ovarian cancer with BRCA1 and BRCA2 mutations - Authors' reply.
    Kristeleit R; Oza AM
    Lancet Oncol; 2022 Jul; 23(7):e315. PubMed ID: 35772457
    [No Abstract]   [Full Text] [Related]  

  • 9. Effect of Oophorectomy on Survival After Breast Cancer in BRCA1 and BRCA2 Mutation Carriers.
    Metcalfe K; Lynch HT; Foulkes WD; Tung N; Kim-Sing C; Olopade OI; Eisen A; Rosen B; Snyder C; Gershman S; Sun P; Narod SA
    JAMA Oncol; 2015 Jun; 1(3):306-13. PubMed ID: 26181175
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Veliparib and topotecan for patients with platinum-resistant or partially platinum-sensitive relapse of epithelial ovarian cancer with BRCA negative or unknown BRCA status.
    Hjortkjær M; Kanstrup H; Jakobsen A; Steffensen KD
    Cancer Treat Res Commun; 2018; 14():7-12. PubMed ID: 30104007
    [No Abstract]   [Full Text] [Related]  

  • 11. Is It time to stratify for BRCA mutation status in therapeutic trials in ovarian cancer?
    Kauff ND
    J Clin Oncol; 2008 Jan; 26(1):9-10. PubMed ID: 18165631
    [No Abstract]   [Full Text] [Related]  

  • 12. Genetic Testing After Previous BRCA Testing: A Case Study.
    Ward M
    Clin J Oncol Nurs; 2016 Dec; 20(6):660-663. PubMed ID: 27857264
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Germline BRCA testing is moving from cancer risk assessment to a predictive biomarker for targeting cancer therapeutics.
    Moreno L; Linossi C; Esteban I; Gadea N; Carrasco E; Bonache S; Gutiérrez-Enríquez S; Cruz C; Díez O; Balmaña J
    Clin Transl Oncol; 2016 Oct; 18(10):981-7. PubMed ID: 26742938
    [TBL] [Abstract][Full Text] [Related]  

  • 14. BRCA-related ovarian carcinoma.
    Rubin SC
    Cancer; 2003 May; 97(9):2127-9. PubMed ID: 12712461
    [No Abstract]   [Full Text] [Related]  

  • 15. Prevalence of BRCA1/BRCA2 mutations in a Brazilian population sample at-risk for hereditary breast cancer and characterization of its genetic ancestry.
    Fernandes GC; Michelli RA; Galvão HC; Paula AE; Pereira R; Andrade CE; Felicio PS; Souza CP; Mendes DR; Volc S; Berardinelli GN; Grasel RS; Sabato CS; Viana DV; Mauad EC; Scapulatempo-Neto C; Arun B; Reis RM; Palmero EI
    Oncotarget; 2016 Dec; 7(49):80465-80481. PubMed ID: 27741520
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Ovarian cancer patients at high risk of BRCA mutation: the constitutional genetic characterization does not change prognosis.
    Sabatier R; Lavit E; Moretta J; Lambaudie E; Noguchi T; Eisinger F; Cherau E; Provansal M; Livon D; Rabayrol L; Popovici C; Charaffe-Jauffret E; Sobol H; Viens P
    Fam Cancer; 2016 Oct; 15(4):497-506. PubMed ID: 26833043
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Family history predictors of BRCA1/BRCA2 mutation status among Tunisian breast/ovarian cancer families.
    Riahi A; Ghourabi ME; Fourati A; Chaabouni-Bouhamed H
    Breast Cancer; 2017 Mar; 24(2):238-244. PubMed ID: 27025497
    [TBL] [Abstract][Full Text] [Related]  

  • 18. BRCA-associated ovarian cancer: from molecular genetics to risk management.
    Girolimetti G; Perrone AM; Santini D; Barbieri E; Guerra F; Ferrari S; Zamagni C; De Iaco P; Gasparre G; Turchetti D
    Biomed Res Int; 2014; 2014():787143. PubMed ID: 25136623
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Variability in Cancer Risk with BRCA Mutations.
    Cancer Discov; 2015 Jul; 5(7):OF16. PubMed ID: 25952264
    [No Abstract]   [Full Text] [Related]  

  • 20. Baseline clinical predictors of antitumor response to the PARP inhibitor olaparib in germline BRCA1/2 mutated patients with advanced ovarian cancer.
    Rafii S; Gourley C; Kumar R; Geuna E; Ern Ang J; Rye T; Chen LM; Shapira-Frommer R; Friedlander M; Matulonis U; De Greve J; Oza AM; Banerjee S; Molife LR; Gore ME; Kaye SB; Yap TA
    Oncotarget; 2017 Jul; 8(29):47154-47160. PubMed ID: 28454085
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.